Leiva Santana C, Galvañ Berenguer B, Gómez García J, Cabello López J
Servicio de Neurología, Hospital General Universitario de Alicante.
Neurologia. 1996 Jan;11(1):1-9.
We switched 50 patients with Parkinson's disease and motor fluctuations from standard levodopa (L-S) to controlled-release carbidopa/levodopa (L-CR). Ten (20%) patients stopped treatment due to adverse events. Data on the 40 patients who completed 6 months of treatment were analyzed. Parkinsonian assessments were performed using the Unified Parkinson's Disease Rating scale (UPDRS) and a nocturnal rating scale. During treatment with L-CR the total daily dose of levodopa increased and the number of daily doses decreased. After changing to L-CR, patients also experienced significant improvement on sub-scales II and III of UPDRS and on the Schwab and England and nocturnal mobility scales. The proportion of "off" time decreased but the duration and severity of dyskinesias increased. Most of the patients who dropped out of the L-CR group had already experienced some type of adverse event during treatment with L-S. At the end of the study, the number of patients preferring L-CR was significantly higher than the number preferring L-S.
我们将50例患有帕金森病且存在运动波动的患者从标准左旋多巴（L-S）转换为控释卡比多巴/左旋多巴（L-CR）。10例（20%）患者因不良事件停止治疗。对完成6个月治疗的40例患者的数据进行了分析。使用统一帕金森病评定量表（UPDRS）和夜间评定量表进行帕金森病评估。在使用L-CR治疗期间，左旋多巴的每日总剂量增加，每日服药次数减少。转换为L-CR后，患者在UPDRS的II和III分量表以及施瓦布和英格兰量表和夜间活动量表上也有显著改善。“关”期的比例下降，但异动症的持续时间和严重程度增加。退出L-CR组的大多数患者在使用L-S治疗期间已经经历过某种不良事件。在研究结束时，更喜欢L-CR的患者数量显著高于更喜欢L-S的患者数量。
